SCHEDULE 13G: Sio Capital Management Discloses Significant Stake in Ventyx Biosciences

Sio Capital Management, LLC has reported a 5.72% beneficial ownership stake in Ventyx Biosciences, Inc., holding over 4 million shares as of December 31, 2024.

Summary

• Sio Capital Management, LLC, a Delaware limited liability company and registered investment adviser, has filed a Schedule 13G indicating beneficial ownership of 4,046,797 shares of Ventyx Biosciences, Inc. common stock.
• This ownership represents 5.72% of Ventyx Biosciences, Inc.'s outstanding common stock.
• Sio Capital Management, LLC holds these shares with shared voting power and shared dispositive power, meaning it directs the voting and disposition of these shares.
• The percentage of class is calculated based on 70,710,667 shares of common stock outstanding as of November 4, 2024, as reported in Ventyx Biosciences' Form 10-Q filed with the SEC on November 7, 2024.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ventyx Biosciences, Inc.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The presence of a significant institutional investor (Sio Capital Management) taking a 5.72% stake can be viewed as a mild positive signal of confidence in the company, hence a slightly positive score.

Positives

• The disclosure of a significant stake (5.72%) by an institutional investment adviser like Sio Capital Management, LLC may signal confidence in Ventyx Biosciences, Inc.'s future prospects.
• Institutional ownership can often be viewed positively by the market as it suggests professional due diligence and long-term interest in the company.

Negatives

• The document, being a beneficial ownership report, does not contain any negative information regarding Ventyx Biosciences, Inc.'s operations or financial performance.

Risks

• The document itself, as a beneficial ownership report, does not detail specific operational or financial risks of Ventyx Biosciences, Inc. It primarily focuses on the nature and extent of the reported ownership.

Future Outlook

The document, a beneficial ownership report, does not provide any forward-looking statements or guidance regarding Ventyx Biosciences, Inc.'s future operations or financial performance.

Industry Context

This filing indicates an institutional investment adviser's interest in Ventyx Biosciences, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such filings are common in industries where institutional investors actively manage portfolios and take significant positions in publicly traded companies, signaling potential market confidence or strategic interest.

Comparison to Industry Standards

• This document is a beneficial ownership report (Schedule 13G) and does not contain financial or operational results that can be compared to industry standards or specific comparable companies/projects. Its sole purpose is to disclose a significant ownership stake.

Related Party Transactions

• Sio Capital Management, LLC acts as an investment adviser to certain affiliated funds that directly hold the shares. Sio GP, LLC acts as the general partner to these clients, and both Sio and Sio GP, LLC are controlled by Michael Castor, who may be deemed to control the voting and dispositive decisions over the reported shares.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence investor sentiment and potentially the stock price, indicating institutional confidence or interest in Ventyx Biosciences, Inc.

Next Steps

• The document does not mention any specific future actions, events, or milestones for Ventyx Biosciences, Inc. or Sio Capital Management, LLC beyond the filing itself.

Key Dates

Keywords

Ventyx Biosciences, Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, VXBT